Strategic Wealth Investment Group LLC Sells 5,374 Shares of AbbVie Inc. $ABBV

Strategic Wealth Investment Group LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 12.7% during the second quarter, HoldingsChannel reports. The fund owned 37,016 shares of the company’s stock after selling 5,374 shares during the period. Strategic Wealth Investment Group LLC’s holdings in AbbVie were worth $9,315,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ABBV. Carret Asset Management LLC increased its stake in AbbVie by 1.6% during the 2nd quarter. Carret Asset Management LLC now owns 50,635 shares of the company’s stock valued at $12,742,000 after purchasing an additional 796 shares in the last quarter. Mindset Wealth Management LLC lifted its stake in shares of AbbVie by 5.0% in the second quarter. Mindset Wealth Management LLC now owns 7,694 shares of the company’s stock worth $1,936,000 after buying an additional 363 shares in the last quarter. Nicholas Hoffman & Company LLC. grew its holdings in shares of AbbVie by 0.7% during the second quarter. Nicholas Hoffman & Company LLC. now owns 10,274 shares of the company’s stock valued at $2,585,000 after buying an additional 71 shares during the last quarter. Todd Asset Management LLC grew its holdings in shares of AbbVie by 16.6% during the second quarter. Todd Asset Management LLC now owns 282,442 shares of the company’s stock valued at $71,074,000 after buying an additional 40,131 shares during the last quarter. Finally, Journey Advisory Group LLC increased its position in shares of AbbVie by 0.4% during the second quarter. Journey Advisory Group LLC now owns 47,472 shares of the company’s stock valued at $11,946,000 after acquiring an additional 181 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Bank of America increased their target price on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Royal Bank Of Canada upped their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Stock Up 0.2%

ABBV opened at $265.62 on Monday. The stock has a market capitalization of $469.29 billion, a price-to-earnings ratio of 75.03, a PEG ratio of 0.88 and a beta of 0.30. The firm has a 50 day moving average price of $248.48 and a 200-day moving average price of $227.50. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the company posted $2.97 earnings per share. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.